Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG0070 Injection in BCG-unresponsive NMIBC (China, Phase II)
CTR20254778Phase 2Active
- Sponsor
- CG Oncology, Inc.
- Start
- Dec 2025
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of cretostimogene grenadenorepvec in bladder cancer, sponsored by CG Oncology, Inc.. Started Dec 2025; status: active.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
bladder cancer
Beyond the preview
Go deeper on CTR20254778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254778.